Notogen is an early-stage biotechnology company developing a non-cellular regenerative biological therapy for degenerative disc disease (DDD). Notogen has compelling pre-clinical data (including large animal in vivo data) and we are currently seeking investors or partners to support a Phase 1/2a clinical trial planned for 2021. DDD is a huge market opportunity, with high prevalence, healthcare cost burden and unmet need. DDD is a leading cause of disability worldwide, frequently manifesting as debilitating chronic back and neck pain. There are currently no approved disease modifying treatments for DDD, with treatment options being primarily limited to pain relief (largely opioid prescriptions) and/or highly invasive and costly surgeries such as spinal fusions. Notogen’s lead product candidate, NTG-101, is a novel, disease-modifying biologic therapy for DDD that suppresses pain and inflammation in spinal discs, stops disc degeneration and induces a regenerative effect within the disc.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):